INTS MEXC RealStocks
Own real INTS shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 05:25:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Intensity Therapeutics, Inc. (INTS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $2.65, with a market capitalization of $10.13M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $2.55 to $15.00. This page covers its latest market performance, valuation, price trends and company information.
$10.13M | |
$2.67 | |
$2.82 | |
$2.55 | |
$2.67 | |
20.37K | |
22.68K | |
-- | |
$15.00 | |
$2.55 | |
-- | |
2026-09-30 |
Intensity Therapeutics, Inc. (INTS) last closed at $2.65 as of 2026-11-19 00:51:00, down 2.62% ($0.07) from the previous close of $2.67.
During the latest regular trading session, INTS traded between $2.55 and $2.82, with a volume of 20.37K shares. The closing price was near the middle and near the lower end of its 52-week range.
Over the past seven days, Intensity Therapeutics, Inc. (INTS) moved from $3.15 to $2.65, representing a decline of 15.97% ($0.50).
The stock traded between $2.55 and $3.39 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 19.42 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.8%
INTS is currently trading at $2.65, placing it 0.8% of the way from its 52-week low of $2.55 to its 52-week high of $15.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Intensity Therapeutics Inc is a late-stage clinical biotechnology company passionately committed to applying scientific leadership in the field of localized cancer reduction to anti-cancer immune activation. Its new approach involves the direct injection into tumors of a product created from DfuseRxSM discovery platform. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its product candidate, INT230-6 comprised of three components: cisplatin, a anti-cancer cytotoxic agent, vinblastine sulfate, also a anti-cancer cytotoxic agent, and an amphiphilic molecule which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 7 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Intensity Therapeutics, Inc. (INTS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to INTS, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between INTS shares and USD.
INTS Shares to USD
1.00 INTS shares = 2.647 USD
Calculations are estimates based on the latest available price and are for reference only.